Choice of an adjuvant for vaccination trials;Choix d'un adjuvant lors d'essais de vaccination

Annales de Medecine Veterinaire

Volumn 147, Issue 6, 2003, Pages 393-401

  Vermout, S ^a   Denis, M ^b   Losson, B ^a   Mignon, B ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; AMINE; ANTIGEN; BACTERIAL TOXIN; FREUND ADJUVANT; ISCOM; MURAMYL DIPEPTIDE; MURAMYL DIPEPTIDE DERIVATIVE; OLIGONUCLEOTIDE; PHOSPHORYL LIPID A; POLYSACCHARIDE; QUINOLONE DERIVATIVE; RECOMBINANT CYTOKINE; SAPONIN DERIVATIVE;

ANIMAL WELFARE; DRUG ACTIVITY; DRUG INDICATION; DRUG SAFETY; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; LYMPHOCYTE ACTIVATION; NONHUMAN; PROPHYLAXIS; REVIEW; TH1 CELL; TUMOR; VACCINATION; VACCINE PRODUCTION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 3042545749     PISSN: 00034118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. AHLERS J.D., BELYAKOV I.M., BERZOFSKY J.A. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med., 2003, 3, 285-301.
2. ALLISON A.C., BYARS N.E. Syntex Adjuvant Formulation. Res. Immunol., 1992, 143, 475-582.
3. AUDIBERT F.M., LISE L.D. Adjuvants: current status, clinical perspectives and future prospects. Trends Pharmacol. Sci., 1993, 14, 174-178.
4. BARR T.A., McCORMICK A.L., CARLRING J., HEATH A.W. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology, 2003, 109, 87-92.
5. BILLIAU A., MATTHYS P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol., 2001, 70, 849-860.
6. BUATES S., MATLASHEWSKI G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis., 1999, 179, 1485-1494.
7. CARLRING J., BARR T.A., BUCKLE A.M., HEATH A.W. Anti-CD28 has a potent adjuvant effect on the antibody response to soluble antigens mediated through CTLA-4 by-pass. Eur. J. immunol., 2003, 33, 135-142.
8. CARSON D.A., RAZ E. Oligonucleotide Adjuvants for T helper 1 (Th1)-specific Vaccination. J. Exp. Med., 1997, 186, 1621-1622.
9. CARSON W.E., YU H., DIERKSHEIDE J., PFEFFER K., BOUCHARD P., CLARK R., DURBIN J., BALDWIN A.S., PESCHON J., JOHNSON P.R., KU G., BAUMANN H., CALIGIURI M.A. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol., 1999, 162, 4943-4951.
10. CEDARLANE LABORATORIES LIMITED. The adjuvant guide. [enligne] (2003). Adresse URL: http://www.cedarlanelabs.com/catalogues.asp?company=AdjuvantGuide Consulté le 27/01/03.
11. CHU R.S., TARGONI O.S., KRIEG A.M., LEHMANN P.V., HARDING C.V. CpG oligonucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med., 1997, 186, 1623-1631.
12. CITTERIO S., RESCIGNO M., FOTI M., GRANUCCI F., AGGUJARO D., GASPERI C., MATYSZAK M.K., GIROLOMONI G., RICCIARDI-CASTAGNOLI P. Dendritic cells as natural adjuvants. Methods, 1999, 19, 142-147.
13. COMOY E., CAPRON A., THYPHRONITIS G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int. Immunol., 1997, 9, 523-531.
14. CONSEIL CANADIEN DE PROTECTION DES ANIMAUX. Lignes directrices: production d'anticorps. [en ligne] (2002). Adresse URL: http:// www.ccac.ca/french/gdlines/antibody/antibodyfr.pdf Consulté le 27/01/03.
15. COX J.C., COULTER A.R. Adjuvants: a classification and review of their mode of action. Vaccine, 1997, 15, 248-256.
16. DALPKE A., ZIMMERMANN S., HEEG K. Immunopharmacology of CpG DNA. Biol. Chem., 2002, 383, 1491-1500.
17. DOCKRELL D.H., KINGHORN G.R. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother., 2001, 48, 751-755.
18. GRISWOLD R. CHUA guidelines concerning use of polyclonal antibody generation/production. State University of New York. [en ligne] (2002). Adresse URL: http:// www.upstate.edu/dlar/hsconly/Policies/guide_antibody.htm Consulté le 27/01/03.
19. GRUN J.L., MAURER P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell. Immunol., 1989, 121, 134-145.
20. HALPERIN S.A., VAN NEST G., SMITH B., ABTAHI S., WHILEY H., EIDEN J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine, 2003, 21, 2461-2467.
21. HALPERN M.D., KURLANDER M.J., PISETSKY D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell. Immunol., 1996, 67, 72-78.
22. HILGERS L.A.T., SNIPPE H. DDA as an immunological adjuvant. Res. Immunol., 1992, 143, 494-501.
23. HOGENESCH H. Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine, 2002, 20: Suppl 3, S34-9.
24. HORZINEK M.C., SCHIJNS V.E.C.J., DENIS M., DESMETTRE P., BABIUK L.A. Adjuvants and vehicles. In: Pastoret P.P., Blancou J., Vannier P., Verschueren C. (Eds.), Veterinary Vaccinology. Elsevier: Amsterdam, 1997, 140-148.
25. HUNTER R.L. Overview of vaccine adjuvants: present and future. Vaccine, 2002, 20: Suppl 3, S7-12.
26. JÄGER E., RINGHOFFER M., DIENES H.P., ARAND M., KARBACH J., JÄER D., ILSEMANN C., HAGEDORN M., OESCH F., KNUTH A. Granulocyte- Macrophage-Colony-Stimulating Factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer., 1996, 67, 54-62.
27. JENSEN F.C., SAVARY J.R., DIVELEY J.P., CHANG J.C. Adjuvant activity of incomplete Freund's adjuvant. Adv. Drug Deliv. Rev., 1998, 32, 173-186.
28. KANDIMALLA E.R., YU D., AGRAWAL S. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther., 2002, 4, 122-129.
29. MOINGEON P., HAENSLER J., LINDBERG A. Towards the rational design of Th1 adjuvants. Vaccine, 2001, 19, 4363-4372.
30. MURRAY R., COHEN P., HARDEGREE M.C. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy, 1972, 30, 146-151.
31. MUTWIRI G., PONTAROLLO R., BABIUK S., GRIEBEL P., VAN DRUNEN LITTEL-VAN DEN HURK S., MENA A., TSANG C. ALCON V., NICHANI A., IOANNOU X., GOMIS S., TOWNSEND H., HECKER R., POTTER A., BABIUK L.A. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet. Immunol. Immunopathol., 2003, 91, 89-103.
32. NICKLAS W. Aluminium salts. Res. Immunol., 1992, 143, 489-494.
33. O'HAGAN D.T. Recent developments in vaccine delivery. Curr. Drug Targets Infect. Disord., 2001, 1, 273-286.
34. PERSING D.H., COLER R.N., LACY M.J., JOHNSON D.A., BALDRIDGE J.R., HERSHBERG R.M., REED S.G. Taking toll:lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol., 2002, 10 suppl, S32-S37.
35. RELYVELD E.H. Preparation and use of calcium phosphate adsorbed vaccines. Dev. Biol. Stand., 1986, 65, 131-136.
36. RIZZA P., FERRANTINI M., CAPONE I., BELARDELLI F. Cytokines as natural adjuvants for vaccines: where are we now? Trends Immunol., 2002, 23, 381-383.
37. SCHIJNS V.E. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol., 2001, 21, 75-85.
38. SEEBER S.J., WHITE J.L., HEM S.L. Predicting the absorption of proteins by aluminium-containing adjuvants. Vaccine, 1991, 9, 201-203.
39. SJOLANDER A., COX J.C. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv. Drug Deliv. Rev., 1998, 34, 321-338.
40. STANLEY M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol., 2002, 27, 571-577.
41. VAN DER LUBBEN I.M., VERHOEF J.C., BORCHARD G., JUNGINGER H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev., 2001, 52, 139-144.
42. WEERATNA R.D., McCLUSKIE M.J., XU Y., DAVIS H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine, 2000, 18, 1755-1762.
43. ZIMMERMAN S., HEEG K., DALPKE A. Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3′ sequence modifications. Vaccine, 2003, 21, 990-995.